{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:44:41Z","timestamp":1773110681288,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 21-year-old Malay woman first presented to our hospital at the age of 16 years with 1-year history of reduced vision and 2 years of amenorrhea. Her baseline prolactin level was 255,894 \u00b5IU\/mL with secondary hypogonadism, and pituitary magnetic resonance imaging revealed a giant prolactinoma (2.8\u00a0\u00d7\u00a03.2\u00a0\u00d7\u00a04.2 cm<jats:sup>3<\/jats:sup>) with suprasellar extension and optic chiasmal compression. She was initially treated with cabergoline, and reductions in the prolactin level and tumor mass were achieved, leading to vision improvement and resumption of normal menstruation. However, she developed recurrent tumor growth and hyperprolactinemia, causing relapse of symptoms, and she needed surgery. Eventually, despite three tumor debulking surgeries and escalation of cabergoline doses up to 1 mg\/day, her tumor progressed with aggressive characteristics. Following a multidisciplinary meeting, the patient is initiated on temozolomide therapy after considering the long-term side effects of radiotherapy in her case.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case highlights the importance of early identification of treatment-resistant prolactinoma and the need for a multidisciplinary approach in managing aggressive prolactinoma in young patients, particularly regarding timely implementation of temozolomide therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03390-y","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:03:45Z","timestamp":1651273425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aggressive giant prolactinoma: a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-0930","authenticated-orcid":false,"given":"Marisa Khatijah","family":"Borhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence Hui Sieng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"1","key":"3390_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000495184","volume":"109","author":"I Shimon","year":"2019","unstructured":"Shimon I. Giant prolactinomas. Neuroendocrinology. 2019;109(1):51\u20136. https:\/\/doi.org\/10.1159\/000495184.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"3390_CR2","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213\u201327. https:\/\/doi.org\/10.1530\/EJE-14-0013.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"3390_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients [published correction appears in Eur J Endocrinol. 2012 Dec;167(6):887]. Eur J Endocrinol. 2012;167(5):651\u201362. https:\/\/doi.org\/10.1530\/EJE-12-0236.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"3390_CR4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1\u201324. https:\/\/doi.org\/10.1530\/EJE-17-0796.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3390_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"19","author":"I Shimon","year":"2016","unstructured":"Shimon I, Sosa E, Mendoza V, et al. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19(4):429\u201336. https:\/\/doi.org\/10.1007\/s11102-016-0723-4.","journal-title":"Pituitary"},{"issue":"1","key":"3390_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00701-017-3396-5","volume":"160","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Regazzo D, Barbot M, et al. Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien). 2018;160(1):49\u201355. https:\/\/doi.org\/10.1007\/s00701-017-3396-5.","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"3390_CR7","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.3171\/foc.2004.16.4.3","volume":"16","author":"JK Liu","year":"2004","unstructured":"Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus. 2004;16(4):e2. https:\/\/doi.org\/10.3171\/foc.2004.16.4.3.","journal-title":"Neurosurg Focus"},{"issue":"7","key":"3390_CR8","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180\u20136. https:\/\/doi.org\/10.1210\/jcem.87.7.8645.","journal-title":"J Clin Endocrinol Metab"},{"issue":"45","key":"3390_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013198","volume":"97","author":"YL Han","year":"2018","unstructured":"Han YL, Chen DM, Zhang C, Pan M, Yang XP, Wu YG. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Medicine (Baltimore). 2018;97(45): e13198. https:\/\/doi.org\/10.1097\/MD.0000000000013198.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3390_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","volume":"20","author":"C Halevy","year":"2017","unstructured":"Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary. 2017;20(2):261\u20136.","journal-title":"Pituitary"},{"issue":"2","key":"3390_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14310\/horm.2002.1729","volume":"16","author":"MH Almalki","year":"2017","unstructured":"Almalki MH, Aljoaib NN, Alotaibi MJ, et al. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens). 2017;16(2):139\u201349. https:\/\/doi.org\/10.14310\/horm.2002.1729.","journal-title":"Hormones (Athens)"},{"issue":"3","key":"3390_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265\u201376. https:\/\/doi.org\/10.1530\/EJE-17-0933.","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03390-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:03:48Z","timestamp":1651273428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03390-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3390"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03390-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}